Augmentin 1: Early Ruling Favors Generics
February 21, 2002 Introduction. Augmentin (an oral, anti-bacterial drug) is a combination of amoxicillin and potassium clavulnate (a beta-lactamase inhibitor). [...]
Augmentin 2: Federal Trial Judge splits decision
March 1, 2002 GlaxoSmithKline announced that a federal judge in the United States District Court for the Eastern District of [...]
Fosamax Weekly: Merck Retains Exclusivity until 2018
April 30, 2003 INTRODUCTION Merck’s patent infringement suit against Teva came to trial in Wilmington, Delaware from March 4 to [...]
Fosamax® Daily: Appeals Court Will Rule for Merck
June 3, 2003 INTRODUCTION On June 3, 2003, the Court of Appeals for the Federal Circuit heard oral argument in [...]
Fosmax Daily: Merck will retain exclusivity until 2007
May 16, 2002 Introduction. Teva and IVAX’s legal efforts to launch a generic osteoporosis drug to compete with Merck’s Fosamax [...]
Fosmax: Courts Uphold Merck’s Daily & Weekly patents
(BUSINESS WIRE)–Oct. 30, 2003 Oct. 30, 2003–Merck & Co., Inc. announced today that the U.S. Court of Appeals for the [...]
Related Case Type
